Outcome of Board Meeting

Date: June 29, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Outcome of Board Meeting of the Company held on Monday, June 29, 2026 Dear Sir/Madam, In Compliance with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we wish to inform you that on the recommendation of the Audit Committee, the Board of Directors of the Company at its meeting held today, i.e., Monday, June 29, 2026 has considered and approved the proposed variation in the utilisation of unutilised portion of the Initial Public Offer (“IPO”) proceeds to the extent of ₹ 1000.16 million out of the total primary IPO proceeds of ₹ 5000.00 million, subject to the approval of Shareholders through Postal Ballot. The meeting of the Board of Directors of the Company commenced at 04:15 P.M. (IST) and concluded at 05:00 P.M.(IST) The aforesaid intimation is also being hosted on the website of the Company. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Deval Rajnikant Shah Whole Time Director & CFO DIN:00332722 Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263